ADVERTISEMENT
Generic Drugs
Hikma says that its acquisition of Xellia’s finished dosage form business and a key contract manufacturing agreement in generics have kept its business on track to meet its full-year forecasts.
After a “solid start to the year”, Organon has delivered on analyst expectations with its third quarter results, despite ongoing questions surrounding future growth and market penetration of key compounds. Meanwhile, the firm’s filing for a biosimilar rival to Prolia/Xgeva has been accepted by the FDA.
Two more generics manufacturers have settled claims with 50 US attorneys general that they artificially inflated and manipulated the prices of generic drugs for nearly a decade.
Despite calls to amend the Urban Wastewater Treatment Directive to protect essential and critical medicines, the EU Council gave its final approval.
A significant divestment in the works, complex generic launches, a mammoth antitrust fine in Europe – Teva’s Q3 was busy and bustling, led by strong, double-digit top-line growth and a further rise in guidance for 2024.
After under-delivering on already muted expectations, Biocon's optimistic future was overshadowed by pending FDA inspection outcomes on two of its facilities.
Two more generics manufacturers have reached agreements with 50 US attorneys general settling claims that they artificially inflated and manipulated the prices of generic drugs for nearly a decade.
Biogen has struck another blow against European generic competitors to Tecfidera, after the European Patent Office upheld a dosage patent for the brand that runs until February 2028. Meanwhile, the firm reported flat biosimilars sales in the third quarter of 2024.
Attended by several government delegates, the opening of the multi-million dollar antibiotic plant highlighted the Indian government’s ongoing policy to bolster domestic pharmaceutical manufacturing.
Sandoz has raised its full-year guidance on the back of third-quarter results that saw the firm enjoy growth of more than a tenth, with biosimilars sales up by a whopping 37%.